Alternatives to ticagrelor
1 same-class SPL records vs ticagrelor - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Brilinta
About ticagrelor
Ticagrelor is a drug that helps to prevent blood clots. It is used to lower your risk of heart attack, stroke, and death if you have heart problems.
Used for: Ticagrelor is used to lower the risk of heart attack, stroke, and cardiovascular death. It is for people who have had a heart problem like acute coronary syndrome (ACS) or a heart attack (MI). It can also help prevent blood clots from forming in stents after a stent procedure. Ticagrelor can also reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).
1 P2Y12 Inhibitor (Antiplatelet) peers (wide set)
ticagrelor vs prasugrel · FAERS reaction fields
FAERS top-reaction field "Dyspnoea" shows the widest count spread between ticagrelor and prasugrel in this extract (3,846-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | ticagrelor | prasugrel |
|---|---|---|
| Dyspnoea | 3,952 | 106 |
| Myocardial Infarction | 2,741 | 172 |
| Death | 1,714 | - |
| Fatigue | 1,525 | 71 |
| Chest Pain | 1,445 | 90 |
| Dizziness | 1,223 | 78 |
| Contusion | 1,066 | - |
| Drug Interaction | 929 | 79 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
ticagrelor peer mix vs class inventory
Peer mix
0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for P2Y12 Inhibitor (Antiplatelet): 2 drugs.
Frequently Asked Questions
What same-class SPL records sit beside ticagrelor? ▼
Reading a wide P2Y12 Inhibitor (Antiplatelet) peer set (1 records)
ticagrelor (Brilinta) sits in a wide P2Y12 Inhibitor (Antiplatelet) peer set (1 of 1 class peers shown). Labeled indication field for ticagrelor: Ticagrelor is used to lower the risk of heart attack, stroke, and cardiovascular death.
Top FAERS reaction fields for ticagrelor total 16,383 reports across 10 reactions, set beside prasugrel. Counts are exposure-weighted submissions, not per-patient risk.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for ticagrelor: see also the generic vs brand label guide when reading Brilinta SPL strings.
Read our methodology - how this data is sourced, computed, and verified.